GlassScriptPhysician profile
Wei-Lung Sam Wu
NPI 1922149350
$1,132.47
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $59.80 · 2021: $212 · 2022: $271 · 2023: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $202.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $184.92 | 2019-2023 | Jynarque |
| Fresenius USA Marketing, INC. | $158.27 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $139.84 | 2019-2023 | Lokelma |
| Amgen INC. | $114.91 | 2020-2023 | Tavneos, Parsabiv |
| Mallinckrodt Hospital Products INC. | $92.05 | 2022-2023 | Acthar, Terlivaz |
| Vifor Pharma, INC. | $71.04 | 2022-2023 | Korsuva, Veltassa |
| Akebia Therapeutics INC | $60.29 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.07 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $52.16 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $48.79 | 2019 | |
| Genzyme Corporation | $39.66 | 2021-2023 | |
| Aurinia Pharma U.S., INC. | $29.04 | 2021 | |
| Travere Therapeutics, INC. | $21.66 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $21.65 | 2021 | |
| Daiichi Sankyo INC. | $20.25 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $19.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei-Lung Sam Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.